Manoj Monga, MD
Urology · San Diego, CANPI 1174609127
Payments from drug & device makers
Across 225 payments — averaging $774.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$51K
- Johnson & Johnson$35K
- C. R. Bard, Inc. & Subsidiaries$27K
- Alnylam Pharmaceuticals Inc.$20K
- Cook Incorporated$18K
- Ethicon Endo-surgery Inc.$5K
- plus $18K from 18 others
Across 2 payments — averaging $449.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Steris Instrument Management Services, Inc.$899
What the payments were for
- Consulting fees$65,21742%
- Speaking & faculty fees$67,65044%
- Travel & lodging$15,87510%
- Food & beverage$5,0453%
- Education$5660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 79 | $51,287 |
| Johnson & Johnson | 45 | $35,249 |
| C. R. Bard, Inc. & Subsidiaries | 22 | $26,848 |
| Alnylam Pharmaceuticals Inc. | 9 | $19,939 |
| Cook Incorporated | 8 | $18,020 |
| Ethicon Endo-surgery Inc. | 3 | $5,033 |
| Richard Wolf Medical Instruments Corp. | 6 | $4,643 |
| Novo Nordisk | 6 | $3,931 |
| Ambu Inc. | 4 | $2,262 |
| Coloplast | 5 | $1,537 |
| Cook Medical LLC | 13 | $1,451 |
| KARL Storz Endoscopy-america | 6 | $1,368 |
| Calyxo, Inc. | 2 | $1,047 |
| Cook Research Incorporated | 3 | $825 |
| Medtronic | 2 | $162 |
| Teleflex LLC | 4 | $150 |
| Procept Biorobotics Corporation | 1 | $119 |
| Dornier Medtech America, Inc | 1 | $108 |
| Astellas Pharma US Inc | 1 | $86 |
| EDAP Technomed Inc | 1 | $67 |
| Profound Medical Corp. | 1 | $42 |
| 180 Medical, Inc. | 1 | $28 |
| Cycle Pharmaceuticals Inc | 1 | $27 |
| Travere Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$30,821
- MONARCH$8,684
- S~Curve$7,899
- GENERAL KIDNEY STONE DISEASE$7,341
- Cook$7,235
- Lumenis Pulse 120H$3,250
- Cook Medical Urology$2,460
- OPTIFLEX$1,600
- Rivfloza$1,488
- Cook Medical Dilation/Access$1,183
- RETRACE$1,113
- Cook Medical Lasers$1,108
- CVAC Aspiration System$1,000
- NEPHROSCOPE MIP M$779
- LithoVue$710
- SPEEDICATH$355
- CMOS VIDEO URETEROSCOPE, 8.5 FR. X 675MM$316
- PERCUTANEOUS TRACT KIT$147
- AMS 700 CXR RTE KIT$125
- AquaBeam Robotic System$119
How this compares
$174,249 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 21 | $19,347 |
| Potassium Citrate ErPotassium Citrate | 77 | $3,833 |
| Estradiol | 22 | $2,790 |
| Tamsulosin Hcl | 120 | $1,634 |
| Trospium Chloride | 11 | $1,387 |
| Finasteride | 75 | $1,312 |
| Methenamine Hippurate | 11 | $1,268 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 18 | $415 |
| Oxybutynin Chloride | 11 | $311 |
| Chlorthalidone | 12 | $202 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $68 |
| Allopurinol | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $86 | $19,34721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,324 urology providers in California.
Other urology in San Diego
- Ithaar DerweeshSan Diego$1.6M
- Amirali SalmasiSan Diego$1.3M
- Elward CrawfordSan Diego$866K
- Roger SurSan Diego$741K
- William MoseleySan Diego$379K
- Irwin GoldsteinSan Diego$361K
- Seth BechisSan Diego$311K
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.